Treats hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets…. ANDA 40833, held by Chartwell Rx. Ergocalciferol.
As of Nov 16, 2026, ANDA 40833 (Ergocalciferol), held by Chartwell Rx, was first approved by FDA on May 20, 2009, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Ergocalciferol Capsules, USP are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 20, 2009 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ergocalciferol50,000 IU · capsule;oral | Ergocalciferol | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters